Does clinical method mask significant VTE-related mortality and morbidity in malignant disease

British Journal of Cancer

Volumn 100, Issue 12, 2009, Pages 1837-1841

  Maraveyas, A ^a   Johnson, M ^b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Mortality; Vascular thromboembolism

Indexed keywords

CANCER PATIENT; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; MORTALITY; NEOPLASM; PATIENT CARE; PRIORITY JOURNAL; SHORT SURVEY; THROMBOEMBOLISM;

HUMANS; NEOPLASMS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 67349273363     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605091     Document Type: Short Survey

References (29)

1. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Schünemann HJ (2007) Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev, Issue 3. Art. No.: CD006652. DOI: 10.1002/ 14651858.CD006652
2. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH (2006) Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24: 1112-1118
3. Aujesky D, Roy PM, Le Manach CP, Verschuren F, Meyer G, Obrosky DS, Stone RA, Cornuz J, Fine MJ (2006) Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 27: 476-481
4. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296: 2558-2560
5. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924
6. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189: 162-170
7. Havig O (1977) Deep venous thrombosis and pulmonary embolism: an autopsy study with multiple regression analysis of possible risk factors. Acta Chirurgica Scandinavica 478(Suppl): 1-120
8. Johnson MJ, Sherry K (1997) How do palliative physicians manage venous thromboembolism? Palliat Med 11: 462-468
9. Johnson MJ, Sproule MW, Paul J (1999a) How common is deep venous thrombosis in patients with advanced cancer? - prevalence and associated variables. Clin Oncol 11: 105-110
10. Johnson MJ, Walker ID, Sproule MW, Conkie J (1999b) Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 21: 51-54
11. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, Hostetter G, Harvey J, Taubman MB (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13: 2870-2875
12. Khorana AA, Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5: 655-663
13. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040
14. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490-5505
15. Mandalà M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, Berardi R, Mosconi S, Torri V, Labianca R (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 18: 1660-1665
16. Maraveyas A, Holmes M, Lofts F, Garadi KK, Gardiner E, Sgouros J (2007) Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial. J Clin Oncol, ASCO Annual Meeting Proceedings 25(18S): 4583
17. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007a) National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966
18. Moore MJ, Paruleker W, Ding K (2007b) In reply'. J Clin Oncol 25: 4321-4322
19. NHS Centre for Reviews and Dissemination, University of York (1999) Getting evidence into practice. Eff Health Care 5: 1-16
20. Noble S (2007) The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J 83(985): 671-674
21. Noble SIR, Nelson A, Finlay IG (2008a) Factors influencing hospice thromboprophylaxis policy: a qualitative study. Palliat Med 22: 808-813
22. Noble SIR, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ (2008b) Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9: 577-584
23. O'Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24: 4928-4932
24. Ogren M, Bergqvist D, Wahlanden K, Eriksson H, Sternby NH (2006) Trousseau's syndrome-what is the evidence? A population-based autopsy study. Thromb Haemost 95: 5415
25. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484-3488
26. Sgouros J, Maraveyas A (2008) Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncologica 47: 337-346
27. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007) Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370: 1773-1779
28. Starling N, Rao S, Norman AR, Iveson T, Nicolson M, Coxon F, Middleton G, Daniels F, Cunningham D (2007) Analysis of thromboembolic events (TEs) in the REAL-2 randomised controlled (RCT) study of four chemotherapy regimens for the treatment of oesophagogastric (OG) cancers Proceedings of Gastrointestinal Cancer Symposium (ASCO-GI). Orlando Abs 73: p127
29. VERITY (Venous Thromboembolism Registry) (2007) Fourth Annual Report 2007, Chapter 4. VTE and cancer. www.verityonline.co.uk